Shin-Jeong Lee1, Kyung Hee Kim2, Young-Sup Yoon3,4. 1. Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. 2. From the Division of Cardiology, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle. WMB 3309, Atlanta, GA, 30322, USA. 3. Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. yyoon5@emory.edu. 4. From the Division of Cardiology, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle. WMB 3309, Atlanta, GA, 30322, USA. yyoon5@emory.edu.
Abstract
PURPOSE OF REVIEW: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. RECENT FINDINGS: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.
PURPOSE OF REVIEW: Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. RECENT FINDINGS: Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.
Authors: Marilyn B Nourse; Daniel E Halpin; Marta Scatena; Derek J Mortisen; Nathaniel L Tulloch; Kip D Hauch; Beverly Torok-Storb; Buddy D Ratner; Lil Pabon; Charles E Murry Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-29 Impact factor: 8.311
Authors: Shulamit Levenberg; Justin S Golub; Michal Amit; Joseph Itskovitz-Eldor; Robert Langer Journal: Proc Natl Acad Sci U S A Date: 2002-03-26 Impact factor: 11.205
Authors: Mark P White; Abdul J Rufaihah; Lei Liu; Yohannes T Ghebremariam; Kathryn N Ivey; John P Cooke; Deepak Srivastava Journal: Stem Cells Date: 2013-01 Impact factor: 6.277
Authors: Matthew J Webber; Jörn Tongers; Marie-Ange Renault; Jerome G Roncalli; Douglas W Losordo; Samuel I Stupp Journal: Acta Biomater Date: 2009-07-25 Impact factor: 8.947
Authors: Valeria V Orlova; Francijna E van den Hil; Sandra Petrus-Reurer; Yvette Drabsch; Peter Ten Dijke; Christine L Mummery Journal: Nat Protoc Date: 2014-05-29 Impact factor: 13.491
Authors: Christoph Patsch; Ludivine Challet-Meylan; Eva C Thoma; Eduard Urich; Tobias Heckel; John F O'Sullivan; Stephanie J Grainger; Friedrich G Kapp; Lin Sun; Klaus Christensen; Yulei Xia; Mary H C Florido; Wei He; Wei Pan; Michael Prummer; Curtis R Warren; Roland Jakob-Roetne; Ulrich Certa; Ravi Jagasia; Per-Ola Freskgård; Isaac Adatto; Dorothee Kling; Paul Huang; Leonard I Zon; Elliot L Chaikof; Robert E Gerszten; Martin Graf; Roberto Iacone; Chad A Cowan Journal: Nat Cell Biol Date: 2015-07-27 Impact factor: 28.824
Authors: Cui Li; Oliver Kitzerow; Fujiao Nie; Jingxuan Dai; Xiaoyan Liu; Mark A Carlson; George P Casale; Iraklis I Pipinos; Xiaowei Li Journal: Bioact Mater Date: 2020-09-22